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Glucose-6-phosphate dehydrogenase (G6PD) enzyme was purified from sheep lenses, and the in vitro
effects of dexamethasone on the enzyme’s activity were investigated. Sheep lens glucose-6-phosphate
dehydrogenase was purified 10,000-fold by using ammonium sulphate fractionation and 20 ,50 -ADPSepharose 4B affinity gel chromatography for a yield of 83.8% and a specific activity of 7.6 EU/mg
protein. Enzyme activity was determined by Beutler’s method. Dexamethasone strongly inhibited the
enzyme under in vitro conditions. The I50 value of the dexamethasone was 3.05 mM.
Key Words: Sheep eye lens, dexamethasone, glucose-6-phosphate dehydrogenase.

Introduction
Glucose 6-phosphate dehydrogenase (D-glucose 6-phosphate: NADP+ oxidoreductase, EC 1.1.1.49; G6PD)
is a key enzyme that catalyses the oxidation of D-glucose 6-phosphate to D-glucose-O-lactone 6-phosphate
in the presence of NADP+1,2 . It is well known that the dehydrogenase exists in the oxidative part of
the pentose phosphate metabolic pathway. The major role of the pathway is to produce NADPH, which
is used for the protection of cells against oxidative damage3,4. In addition, NADPH is widely used in
biosynthesis and in drug detoxification5−7. Many enzymes play an important role in maintaining the
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integrity of the lens metabolism8 . The pentose phosphate metabolic pathway functions in the lens to
generate reduced equivalents (NADPH), which are used mainly for the maintenance of reduced glutathione
(GSH) levels8,9 . The mammalian lens contains an usually high concentration of GSH, the highest level
being in the epithelium10. Lens G6PD activity has been investigated in some mammals such as bovine and
rats11,12 .
G6PD deficiency is widespread throughout the world, especially along the Mediterranean coast13 .
This enzyme deficiency is found in all tissues, including the crystalline lens14 . Genetic abnormality and
age may cause deficiency of this enzyme13 . A cataract is usually defined as any opacity in the lens. A
number of studies have revealed a relationship between cataractogenesis and G6PD deficiency15−18 . The
possible causes, mechanisms and biochemical and biophysical changes occurring during cataractogenesis
have been the subject of intense study for many years. It has also been suggested that etiological factors
have important roles in causing cataract development, such as heredity, latitude, exposure to light and
some drugs13,19. Numerous individual causes of cataract exist and often multiple factors act together. The
association between corticosteroid use and posterior subcapsular cataract has been noted consistently20,21 .
The fall in nonprotein and protein –SH could be the first event in the well-known biochemical changes that
occur in steroid-induced cataract. The mechanism underlying steroid-induced damage could be due to a
conformational change of lens crystallins which results in an unmasking of –SH groups with a consequent
increased susceptibility to oxidation21,22.
Dexamethasone is commonly used in the treatment of some inflammatory eye diseases23−26 . We aimed
to investigate the in vitro effects of dexamethasone on lens G6PD activity and to identify a possible adverse
effect such as inhibition of G6PD, which is suggested to be associated with cataract formation.

Materials and Methods
Materials
20 , 50 ’-ADP-Sepharose 4B was obtained from Pharmacia. NADP+ , glucose-6-phosphate, protein assay
reagent and chemicals for electrophoresis were obtained from Sigma Chem. Co. All other chemicals of
analytical grade were obtained from either Sigma or Merck.

In Vitro Studies
Preparation of Homogenate
The lenses were extracted at 4 ◦ C from sheep obtained from a local slaughterhouse. The lenses were washed
3 times with 10 mM Tris-HCl buffer (pH 7.6) containing 1 mM 2-mercaptoethanol (2-ME). The lenses
were pulverised in liquid nitrogen (approximately –163 ◦ C), transferred to 10 mM Tris-HCl buffer (pH 7.6)
containing 1 mM 2-ME, and centrifuged at 4 ◦ C, 39,100 x g for 30 min. Supernatant was used in further
studies27 .

Ammonium Sulphate Fractionation and Dialysis
The homogenate was subjected to precipitation with ammonium sulphate (between 10 and 90%). Ammonium
sulphate was slowly added to the homogenate and constant stirring was used for complete dissolution. This
mixture was centrifuged at 10,000 x g for 15 min and the precipitate was dissolved in 50 mM of phosphate
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buffer (pH 7.0). Enzyme activity was determined both in the supernatant and in the precipitate for each
respective precipitation step. The enzyme was observed to precipitate at the 0-30% precipitation step. The
resultant solution was clear, and contained partially purified enzyme. This solution was dialysed against 4
◦

C in 50 mM K-acetate/50 mM K-phosphate buffer (pH 7.0) for 2 h with 2 changes of buffer28 .

2 0 , 50-ADP Sepharose 4B Affinity Chromatography
Two grams of dried 20 , 50 -ADP Sepharose 4B gel was used for a 10 mL column volume. The gel was washed
with 400 mL distilled water to remove foreign bodies and any air in the swollen gel was eliminated. The gel
was suspended in 0.1 M K-acetate/0.1 M K-phosphate buffer (pH 6.0) and then packed in a small column
(1 x 10 cm) and equilibrated with the same buffer (50 mL). The gel was washed with 0.1 M K-acetate/0.1
M K-phosphate buffer (pH 6.0). The flow rates for washing and equilibration were adjusted by peristaltic
pump 50 mL/h. A dialysed sample obtained previously was loaded on a 20 , 50 -ADP Sepharose 4B affinity
column and the flow rate was adjusted to 20 mL/h. Then the column was sequentially washed with 20 mL
0.1 M K-acetate/0.1 M K-phosphate (pH 6.0), 25 mL of 0.1 M K-acetate/0.1 M K-phosphate (pH 7.85) and
0.1 M KCl/0.1 M K-phosphate (pH 7.85) until the final absorbance was 0.05. Elution was carried out with
80 mM K-phosphate, 80 mM KCl, 0.5 mM NADP+ and 10 mM EDTA (pH 7.85). Eluates were collected in
2 mL tubes and their activity was separately measured as EU/mL. Enzyme activity was measured in final
fractions, and the activity-containing tubes were pooled. All of the procedures were performed at 4 ◦ C28,29.

Activity Determination
The in vitro enzyme activity was investigated as follows: 580 µL of distilled water, 20 µL of sheep lens
G6PD enzyme sample, 100 µL of 2 mM NADP+ , 100 µL of 0.1 M MgCl2 , and 100 µL of 1 M Tris-HCl
buffer (pH 8.0) containing 5 mM EDTA were added to the reference cuvette, and 20 µL of sheep lens G6PD
enzyme sample, 100 µL of 2 mM NADP+ , 100 µL of 0.1 M MgCl2 , 100 µL of 1 M Tris-HCl buffer (pH 8.0)
and 5 mM EDTA containing 100 µL of 6 mM glucose-6-phosphate (G6P) were added to the sample cuvette.
The enzymatic activity was measured by Beutler’s method30 . NADPH produced in the reaction mixture
was measured at 340 nm as absorbance (OD). One unit of enzyme (EU) activity was defined as the enzyme
amount reducing 1 µ mol NADP+ per 1 min at 25 ◦ C, pH 8.0.

Protein Determination
Quantitative protein determination was done spectrophotometrically at 595 nm according to Bradford’s
method, with bovine serum albumin used as a standard31 .

SDS Polyacrylamide Gel Electrophoresis
The purified enzyme was subjected to SDS polyacryamide gel electrophoresis according to Laemmli’s
method32 . It was carried out in 4% and 10% acrylamide concentrations for stacking and running gels
containing 0.1% SDS, respectively. Protein standards, sheep erythrocyte G6PD, and sheep lens G6PD were
applied to the gels (20 µg for each sample and standard). Gels were stained overnight in 0.1% Coomassie
Brilliant Blue R-250 in 50% methanol and 10% acetic acid, then destained with several changes of the same
solvent without dye. The electrophoretic pattern was photographed.
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In vitro studies by dexamethasone
In order to determine the effects of dexamethasone on G6PD, several concentrations of dexamethasone (0.38,
0.77, 1.54, 3.08, 4.38 mM), were added to separate tubes containing purified enzyme. The enzyme activity
was measured in these tubes while taking the tubes containing no drug as a control (100% activity). The
experiments were repeated 3 times. The I50 values were obtained after percent activity was plotted vs.
dexamethasone concentration.

Results
The purification process of sheep lens G6PD is summarised in Table 1. The first step used was ammonium
sulphate fractionation. At intervals of 0-60%, ammonium sulphate saturation was performed in homogenate
and the enzyme in the lens was almost completely separated (99%) from 6-phosphogluconate dehydrogenase
activity by subjecting the supernatant to 0-30% saturated ammonium sulphate fractionation and then
the resulting pellet was dissolved with 50 mM phosphate buffer (pH 7.0). After ammonium sulphate
fractionation, 20 , 50 -ADP Sepharose 4B affinity gel chromatography was followed. The elution profile of
20 , 50 -ADP Sepharose 4B affinity gel chromatography is shown in Figure 1. The procedure of Ninfali et al.
28

was followed to purify the enzyme from sheep lens; specific activity of 7.6 EU/mg protein and 10,000-fold

was achieved with an 83.8% yield (Table).

Activity (EU/mL)

1.6
1.2
0.8
0.4
0
0

5

Fraction Number

10

15

Figure 1. Activity-fraction number profile for elution of G6PD enzyme from 20 ,50 -ADP-Sepharose 4B affinity
chromatography.
Table. Purification scheme of glucose-6-phosphate dehydrogenase from sheep lens.

Purification step
Homogenate
Ammonium
sulphate
precipitation
(0-30%)
saturation
20 ,50 - ADP
Sepharose 4B
affinity
chromatography
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Activity
(EU/mL)

Protein
(mg/mL)

0.012

Total
volume
(mL)
57

Total
activity
(EU)
0.68

Specific
activity
(EU/mg)
0.00076

Yield
(%)

Purification
factor

15.6

Total
protein
(mg)
889.2

100

1

0.12

5

7.16

35.8

0.6

0.017

88.2

22

0.19

3

0.025

0.075

0.57

7.6

83.8

10,000
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Figure 2 exhibits the SDS-PAGE performed for the purity and subunit molecular weight of the enzyme
according to Laemmli’s method32 . The subunit molecular weight was 54,957 Da.

Figure 2. SDS–polyacrylamide gel electrophoresis of G6PD (Lane 1: Protein standards: Rabbit heart creatine
phosphokinase (81 kDa), bovin serum albumin (66 kDa), chicken ovalbumin (45 kDa), and bovine carbonic anhydrase
(29 kDa), horse heart cytochrome C (12.4 kDa); Lane 2 and 3: Sheep erythrocyte G6PD; Lane 4: Sheep lens G6PD).

Our study revealed that dexamethasone concentrations (between 0.38 and 4.38 mM) in vitro at low
concentrations inhibited the G6PD activity of sheep lens. An activity % -[Dexamethasone] graph was drawn
at 0.38, 0.77, 1.54, 3.08, 4.38 mM dexamethasone concentrations (Fig. 3). Dexamethasone concentration
producing 50% inhibition (I50 ) was calculated from an equation on the graph. The I50 value obtained from
in vitro studies was 3.05 mM.
120

y = 3.288x2 - 26.123x + 99.11
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Figure 3. % Activity -[Dexamethasone] graph for G6PD in the presence of dexamethasone.
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Discussion
Many chemicals when administered at relatively low doses affect the metabolism by altering normal enzyme
activity, particularly through the inhibition of a specific enzyme. The effects can be dramatic and systemic33 .
For example, Naveh and Marshall investigated the anti-inflammatory effect of melanocyte-stimulating hormone (MSH), which is a known anti-inflammatory agent, after ocular surgery34 . Additionally, halothane
was found to inhibit red blood cell and liver G6PD enzyme activities significantly in the first week and to
activate this enzyme in the second week of anesthesia compared with a control group35 . In another study,
G6PD enzyme activity was inhibited by melatonin in human erythrocytes in vitro and in rat erythrocytes
in vivo36. G6PD seems to be utilised in the defence mechanism against the free radicals generated in the
metabolism of some drugs. Enzyme deficiency has been shown in some tissues, including the lens15 . G6PD
deficiency is still the most common of all clinically significant enzyme defects in living system biology as a
whole15 . G6PD deficiency plays an important biochemical role in the metabolism of the lens18 , because the
reaction catalysed by G6PD in the lens generates reduced equivalents (NADPH), which are used mainly for
the maintenance of reduced GSH levels4,10. One possible function of GSH in the lens is to maintain the
thiol (-SH) groups of proteins in a reduced state, thus preventing the formation of high molecular weight
protein aggregates10 . Furthermore, GSH may also prevent oxidative damage to the lens10 . Orzalesi et al.
have reported G6PD deficiency to be a predisposing factor for the development of a cataract37 . In addition,
in a study carried out on the erythrocyte and lens, G6PD in senile and presenile cataracts was examined
and it was found that G6PD deficiency might be a cataractous pathogenetic factor for presenile cataract17 .
It has also been suggested that certain etiological factors have important roles in cataract development,
such as heredity, latitude, exposure to light and some drugs such as corticosteroids13,19 . Corticosteroids
have been used to control inflammatory and immunological diseases of the eye. Corticosteroids cause several
adverse reactions, including posterior subcapsular cataract formation20−22. It is known that oxidative stress
occurs after the administration of some drugs in red blood cells and other tissues38−40 . Dexamethasone is a
corticosteroid which is commonly used in the treatment of some inflammatory eye diseases23−26 .
In our study, we investigated the in vitro effects of dexamethasone on sheep lens G6PD activity. For
this purpose, sheep lens G6PD was purified by ammonium sulphate fractionation (0-30%) and 20 , 50 -ADPSepharose 4B affinity gel chromatography (Table and Figure 1) and its purity confirmed by SDS-PAGE
(Figure 2). After overall purification, the G6PD enzyme was obtained with a recovery of 83.8% and a
specific activity of 7.6 U/mg proteins. This enzyme was also purified 10,000-fold (Table). In 1999, Ulusu
et al. reported purifying the G6PD enzyme with a yield of 13.7% , with a specific activity of 2.64 EU/mg
proteins, and 19,700-fold using 20 , 50 -ADP-Sepharose 4B affinity gel chromatography and DEAE-Sepharose
ion exchange column chromatography from bovine lens11 . In addition, the enzyme was purified with a
specific activity of 2.64 EU/mg proteins and 9150-fold from chicken erythrocytes by Yılmaz et al.1
As seen in gel photographs, sheep erythrocyte G6PD and sheep lens G6PD have different subunit
molecular weights (66,880 Da and 54,957 Da, respectively). The subunit molecular weight of sheep lens G6PD
was similar to bovine lens G6PD subunit molecular weight (69 kDa)11. Figure 3 shows that dexamethasone
administration decreased enzyme activity. The I50 value was 3.05 mM.
In conclusion, dexamethasone, which inhibits G6PD activity in the lens, may be a contributing factor
in cataract development. If the administration of dexamethasone to a patient with G6PD deficiency is
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required, routine ophthalmic examinations should be performed. Because sheep lens G6PD may be quite
different from that of the human enzyme, the penetration and dose/effect ratio under clinical settings are
unknown. Further postmortem studies are needed to evaluate the enzyme activity in human lenses as well.
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